APA (7th ed.) Citation

JDC, R., J, W., KA, W., SN, T., DA, L., S, G., . . . C, P. (2025). Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): A phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet (London, England), 405(10489), 1608. https://doi.org/10.1016/S0140-6736(25)00628-2

Chicago Style (17th ed.) Citation

JDC, Ross, et al. "Oral Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhoea (EAGLE-1): A Phase 3 Randomised, Open-label, Non-inferiority, Multicentre Study." Lancet (London, England) 405, no. 10489 (2025): 1608. https://doi.org/10.1016/S0140-6736(25)00628-2.

MLA (9th ed.) Citation

JDC, Ross, et al. "Oral Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhoea (EAGLE-1): A Phase 3 Randomised, Open-label, Non-inferiority, Multicentre Study." Lancet (London, England), vol. 405, no. 10489, 2025, p. 1608, https://doi.org/10.1016/S0140-6736(25)00628-2.